A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
Case: A 62-Year-Old Woman With MetastaticBRAFV600E-Mutated NSCLC
Initial Presentation
- A 62-year-old woman presented with a 4-month history of chronic cough, dyspnea, loss of appetite and weight loss
- PMH/SH: 25 pack-year smoking history, quit 12 years ago
- PE: Right-sided wheezing on auscultation
Clinical Workup
- Labs: WNL
- Chest/abdomen/pelvic CT showed a 2.5-cm solid pulmonary lesion in the left inferior lobe, ipsilateral peribronchial lymph node involvement and multiple small hepatic lesions
- Bronchoscopic biopsy of the lung lesion and lymph node revealed lung adenocarcinoma
- Contrast‐enhanced MRI of the head showed no evidence of metastases
- Molecular and biomarker testing: BRAFV600E+,EGFR-, ALK-, ROS1-,PD-L1 0%
- Stage T1cN1M1c; ECOG PS 0
Treatment and Follow-Up
- Started on dabrafenib 150 mg PO qDay BID + trametinib 2 mg PO qDay; achieved a partial response
- Patient developed intermitted nausea and vomiting, medically controlled
- Imaging at 3,6 and 9 months showed sustained partial response
Related Videos
Related Content
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024Article
At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
